Supernus Pharma (SUPN) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Supernus Announces First Quarter 2016 Financial Results
May 3, 2016 5:00 PM EDTFirst quarter 2016 product prescriptions totaled 114,773, representing a 49.7% increase over the first quarter of 2015.Net product sales for first quarter 2016 were $43.0 million, a 53.1% increase over the first quarter of 2015.Operating income for first quarter 2016 was $5.3 million, a 55.0% increase over the first quarter of 2015.   Diluted earnings per share in the first quarter were $0.08 compared to $0.02 in the same period last year.   The Company remains on track to have data available from the Phase III program for SPN-810, for the treatment of Impulsive Aggression in ADHD, by mid-2017 and from the Phase IIb program for... More
